Evidence map›Paper›PMID 39995769›Full record

ArticleLung Cancer (Auckland, N.Z.)2025

Comprehensive Survey of AACR GENIE Database of Tumor Mutation Burden (TMB) Among All Three Classes (I, II, III) of

Zhaohui Liao Arter, Kevin Shieh, Misako Nagasaka, Sai-Hong Ignatius Ou

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung Cancer (Auckland, N.Z.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Genomic Characteristics of Bladder Cancer: An AACR Project GENIE Study.International journal of molecular sciences · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Zhaohui Liao ArterDivision of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA.ORCID 0000-0001-7394-7156
Kevin ShiehDivision of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA.
Misako NagasakaDivision of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA.ORCID 0000-0001-5308-615X
Sai-Hong Ignatius OuDivision of Hematology-Oncology, University of California Irvine School of Medicine, Orange, CA, USA.ORCID 0000-0002-1764-4975

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Methods: We queried the public AACR GENIE database (version 13.1), which includes tumor mutation burden (TMB) data, to explore potential molecular differences among the three classes of non-small cell lung cancer (NSCLC). Results: Out of 20,713 unique NSCLC patients, 324 (1.6%) were Conclusion: A substantial proportion of

Indexed as

BRAF mutationclass I, II, III mutationsimmunocheck point inhibitor (ICI)NSCLCtarget therapytumor mutation burden (TMB)

Identifiers

PMID39995769
PMCPMC11847431

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.